Come Join Our Commuity Print E-mail
By BioMedReports.Com   
Sunday, 01 November 2015 21:30
We are offering discounted subscription plans to join BioMedReports.com for a limited time.
Read more...
 
GW Pharma Confirms Positive Proof of Data in Schizophrenia Print E-mail
By David Fowler   
Tuesday, 15 September 2015 18:12
Biopharmaceutical firm GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) has confirmed positive top line results from exploratory Phase 2a placebo-controlled clinical trial of Cannabidiol in 88 patients suffering from schizophrenia.
Read more...
 
TESARO Inc (NASDAQ:TSRO) confirms U.S. FDA Approval of VARUBI for Nausea associated with Cancer Chemotherapy Print E-mail
By Josh Gee   
Wednesday, 09 September 2015 22:40
icon_NewsMakersUPOncology-focused biopharmaceutical firm TESARO Inc(NASDAQ:TSRO) has confirmed that U.S. Food and Drug Administration (FDA) has given consent to VARUBI combined with other antiemetic agents in adults for avoiding delayed nausea and vomiting related to repeat courses of emetogenic cancer chemotherapy.
Read more...
 
Corbus Pharma’s Investigational Drug Resunab given fast track status by FDA for the Treatment of Systemic Sclerosis Print E-mail
By David Fowler   
Thursday, 20 August 2015 14:50
Clinical stage drug development firm Corbus Pharmaceuticals Holdings Inc(NASDAQ:CRBP) has confirmed that U.S. Food and Drug Administration has given Fast Track development program the
investigation of Resunab for systemic sclerosis.
Read more...
 
La Jolla Signs Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb Print E-mail
By David Fowler   
Wednesday, 05 August 2015 18:10
Leader of innovative therapies, La Jolla Pharmaceutical Company (NASDAQ:LJPC), has confirmed signing of two exclusive worldwide license agreements for intellectual property rights that would include La Jolla’s next-generation gentamicin derivatives, LJPC-30Sa and LJPC-30Sb.
Read more...
 
Codexis confirms CodeEvolver Technology Transfer and License Agreement With Merck Print E-mail
By William Kent   
Tuesday, 04 August 2015 17:22
Leading developer of biocatalysts for pharma as well as chemical industries Codexis, Inc.(NASDAQ:CDXS) confirmed signing a CodeEvolver platform technology license agreement with Merck. Merck is known as MSD outside Canada as well as US.
Read more...
 
BiondVax’s Vaccine given 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic Print E-mail
By Marilyn Mullen   
Monday, 03 August 2015 17:21
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has confirmed that it would be getting statistical analysis of results from study that shows universal flu vaccine (M-001) of the

Error. Page cannot be displayed. Please contact your service provider for more details. (31)

firm, which was provided in BVX-005 phase II trial that had taken place three years back.
Read more...
 
Novavax Reports positive data from Phase 2 Trial of Quadrivalent Seasonal Influenza VLP Print E-mail
By Marilyn Mullen   
Thursday, 30 July 2015 14:50
Clinical stage vaccine firm Novavax, Inc. (NASDAQ:NVAX) has confirmed positive top-line data from Phase 2clinical trial of the recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate.
Read more...
 
Loxo Oncology and University of Colorado Cancer Center confirm Clinical Validation for LOXO-101 Against TRK Fusion Cancer Print E-mail
By William Kent   
Tuesday, 28 July 2015 20:08
Biopharmaceutical firm Loxo Oncology Inc. (NASDAQ:LOXO) and the University of Colorado Cancer Center has confirmed publication of research brief in online edition of journal Cancer Discovery showing the patient with tropomyosin receptor kinase fusion cancer enrolled in Phase 1 dose escalation trial of LOXO-101, only selective TRK inhibitor in clinical development.
Read more...
 
ZIOPHARM Oncology Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malignant Glioma Print E-mail
By William Kent   
Friday, 24 July 2015 14:57
Biopharmaceutical firm ZIOPHARM Oncology Inc.(NASDAQ:ZIOP) Oncology has confirmed that U.S. Food and Drug Administration (FDA) has given approval to Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in treating the ones who suffer from malignant glioma.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 12

Newsletter

BMR:1